Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages

2015/08/31 by Stefano Ugel, Francesco De Sanctis, Susanna Mandruzzato +1 · 28 citations
Immunology and Microbiology · Medicine · #Immune cells in cancer #Cancer Cells and Metastasis #Cancer Immunotherapy and Biomarkers

paper · pdf · doi:10.1172/jci80006

Abstract

The generation of an inflammatory environment is favorable and often decisive for the growth of both primary tumors and metastases. Tumor cells either express membrane molecules or release tumor-derived soluble factors able to alter myelopoiesis. Tumor-reprogrammed myeloid cells not only create a tolerogenic environment by blocking T cell functions and proliferation, but also directly drive tumor growth by promoting cancer stemness, angiogenesis, stroma deposition, epithelial-to-mesenchymal transition, and metastasis formation. In this Review, we discuss the interplay between immunosuppressive and protumoral myeloid cells and detail their immune-regulatory mechanisms, the molecular pathways involved in their differentiation, as well as their potential role as prognostic and diagnostic biomarkers and prospective targets for innovative approaches to treat tumor-bearing hosts.

Cited by

• Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
• Tumor promoting role of anti-tumor macrophages in tumor microenvironment
• Targeting the tumor microenvironment in cholangiocarcinoma to improve immune checkpoint blockade: potential strategies and translational pre‐clinical models
• Cancer immunotherapy: harnessing the immune system to battle cancer. [europepmc]
• Immune suppressive mechanisms in the tumor microenvironment. [europepmc]
• IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. [europepmc]
• The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. [europepmc]
• Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. [europepmc]
• Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. [europepmc]
• Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. [europepmc]
• Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells. [europepmc]
• Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. [europepmc]
• Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy. [europepmc]
• Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). [europepmc]
• Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. [europepmc]
• Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8 + T Cell-Derived Interferon-γ. [europepmc]
• β2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells. [europepmc]
• High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. [europepmc]
• CCL2/CCR2 signaling in cancer pathogenesis. [europepmc]
• Myocardial infarction accelerates breast cancer via innate immune reprogramming. [europepmc]
• Mechanisms of Cancer Resistance to Immunotherapy. [europepmc]
• Understanding the tumor microenvironment for effective immunotherapy. [europepmc]
• Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages. [europepmc]
• Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting. [europepmc]
• Combination strategies to maximize the benefits of cancer immunotherapy. [europepmc]
• Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. [europepmc]
• Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. [europepmc]
• Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. [europepmc]

Related

• Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
• Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species
• Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism
• Single-cell transcriptome profiling of the myeloid cells repopulating after chemotherapy identifies a neutrophil-like monocyte subset with pro-tumor activities
• Inflammation- and resolution-programmed myeloid circuits govern therapeutic resistance in epithelial and mesenchymal triple-negative breast cancer